ALNYLAM PHARMACEUTICALS, INC.

ALNYLAM PHARMACEUTICALS, INC. is a biopharmaceutical company focused on the research, development, and commercialization of RNA interference therapeutics. Its core capabilities center on oligonucleotide drug design, synthetic chemistry, and delivery system innovation, particularly through lipid nanoparticle and GalNAc-conjugate platforms. The company specializes in silencing disease-causing genes at the mRNA level, enabling precision interventions for rare and chronic conditions. Technical expertise includes target validation, preclinical pharmacology, GMP manufacturing of siRNA molecules, and clinical-stage translational science. Differentiators include proprietary chemistries for enhanced stability and tissue-specific delivery, as well as integrated development pipelines spanning discovery to regulatory submission. No award history is available to infer specific agency engagements or contract patterns. Consequently, there is no demonstrable track record of direct federal contract performance or government program participation. The company operates within the pharmaceutical manufacturing sector, primarily aligned with NAICS 325412, which encompasses the production of therapeutic and preventive agents derived from biotechnology and molecular biology. Its market positioning is rooted in cutting-edge genetic medicine, targeting unmet medical needs through novel mechanisms of action. Vertical specialization includes neurology, hepatology, and cardiovascular disease, with a focus on first-in-class RNAi therapeutics. ALNYLAM PHARMACEUTICALS, INC. is a publicly traded corporation headquartered in Cambridge, Massachusetts, with a corporate structure typical of a large biotech enterprise. The company holds no federal small business or socioeconomic certifications. Its operational footprint is concentrated in Massachusetts, with additional research and manufacturing facilities globally, but there is no evidence of direct engagement with U.S. government procurement programs.